Institution
Eli Lilly and Company
Company•Indianapolis, Indiana, United States•
About: Eli Lilly and Company is a company organization based out in Indianapolis, Indiana, United States. It is known for research contribution in the topics: Population & Agonist. The organization has 17826 authors who have published 22835 publications receiving 946714 citations. The organization is also known as: Eli Lily.
Topics: Population, Agonist, Insulin, Placebo, Olanzapine
Papers published on a yearly basis
Papers
More filters
TL;DR: It is found that 12-month-old PDAPP Abca1-/- mice had a higher percentage of carbonate-insoluble apoE and that apOE deposits co-localize with amyloid plaques, demonstrating that poorly lipidated apo E co-deposits with insoluble Aβ.
303 citations
TL;DR: The results suggest that anti-lg may induce B cell growth via phosphoinositide degradation and Ca2+ mobilization, and that phorbol myristate acetate, and possibly lipopolysaccharide, bypass these initial events.
302 citations
TL;DR: A pragmatic, statistically sound and clinically relevant approach to dose-proportionality analyses that is compatible with common study designs and helps to standardize decision rules is proposed.
Abstract: Purpose. The aim of this work was a pragmatic, statistically sound and clinically relevant approach to dose-proportionality analyses that is compatible with common study designs.
302 citations
TL;DR: An important role for IL-1β, IL-6, and TNF-α in the pathophysiology of suicidal behavior is suggested and that proinflammatory cytokines may be an appropriate target for developing therapeutic agents are suggested.
302 citations
Johnson & Johnson1, Critical Path Institute2, Fox Chase Cancer Center3, Food and Drug Administration4, University of Michigan5, Daiichi Sankyo6, National Institutes of Health7, Georgetown University8, Merck Serono9, University of Hamburg10, Foundation for the National Institutes of Health11, Genentech12, GlaxoSmithKline13, Eli Lilly and Company14, Memorial Sloan Kettering Cancer Center15
TL;DR: Methods for interactive comparisons of proprietary new technologies, clinical trial designs, a clinical validation qualification strategy, and an approach for effectively carrying out this work through a public-private partnership that includes test developers, drug developers,clinical trialists, the US Food & Drug Administration and the US National Cancer Institute are described.
Abstract: This manuscript summarizes current thinking on the value and promise of evolving circulating tumor cell (CTC) technologies for cancer patient diagnosis, prognosis, and response to therapy, as well as accelerating oncologic drug development. Moving forward requires the application of the classic steps in biomarker development–analytical and clinical validation and clinical qualification for specific contexts of use. To that end, this review describes methods for interactive comparisons of proprietary new technologies, clinical trial designs, a clinical validation qualification strategy, and an approach for effectively carrying out this work through a public-private partnership that includes test developers, drug developers, clinical trialists, the US Food & Drug Administration (FDA) and the US National Cancer Institute (NCI).
302 citations
Authors
Showing all 17866 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Mark J. Daly | 204 | 763 | 304452 |
| Irving L. Weissman | 201 | 1141 | 172504 |
| Eric J. Topol | 193 | 1373 | 151025 |
| Tony Hunter | 175 | 593 | 124726 |
| Xiang Zhang | 154 | 1733 | 117576 |
| Jerrold M. Olefsky | 143 | 595 | 77356 |
| Stephen F. Badylak | 133 | 530 | 57083 |
| George A. Bray | 131 | 896 | 100975 |
| Lloyd Paul Aiello | 131 | 506 | 85550 |
| Levi A. Garraway | 129 | 366 | 99989 |
| Mark Sullivan | 126 | 802 | 63916 |
| James A. Russell | 124 | 1024 | 87929 |
| Tony L. Yaksh | 123 | 806 | 60898 |
| Elisabetta Dejana | 122 | 430 | 48254 |
| Hagop S. Akiskal | 118 | 565 | 50869 |